GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™). (Source: GSK news)
Source: GSK news - June 25, 2014 Category: Pharmaceuticals Source Type: news
GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes
New data from secondary analyses of four randomised phase III studies being presented at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco (Source: GSK news)
Source: GSK news - June 14, 2014 Category: Pharmaceuticals Source Type: news
GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia
GlaxoSmithKline (GSK) plc today announced the results from the Phase III PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in paediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP). Eltrombopag—marketed as Promacta™ in the U.S. and as Revolade™ in Europe and other countries across the world—met its primary endpoint. (Source: GSK news)
Source: GSK news - June 13, 2014 Category: Pharmaceuticals Source Type: news
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland Ltd (Janssen) for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant). (Source: GSK news)
Source: GSK news - June 12, 2014 Category: Pharmaceuticals Source Type: news
GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD
GlaxoSmithKline plc (LSE/NYSE:GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies (Source: GSK news)
Source: GSK news - June 11, 2014 Category: Pharmaceuticals Source Type: news
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome. (Source: GSK news)
Source: GSK news - June 5, 2014 Category: Pharmaceuticals Source Type: news
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
GlaxoSmithKline plc (LSE: GSK) today announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab as adjuvant treatment for HER2 positive early breast cancer (Source: GSK news)
Source: GSK news - June 1, 2014 Category: Pharmaceuticals Source Type: news
Serious Fraud Office Investigation
GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK’s Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group’s commercial practices. (Source: GSK news)
Source: GSK news - May 27, 2014 Category: Pharmaceuticals Source Type: news
GSK and Genmab receive CHMP positive opinion for Arzerra (ofatumumab) in combination with chlorambucil or bendamustine as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) who are not eligible for fludarabine-based therapy
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation to the terms of the marketing authorisation for Arzerra™ (ofatumumab) for a new indication in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. (Source: GSK news)
Source: GSK news - May 23, 2014 Category: Pharmaceuticals Source Type: news
GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan
GSK announced the submission of a regulatory application to the Japanese MHLW for UMEC a LAMA, administered using the Ellipta™ dry powder inhaler. (Source: GSK news)
Source: GSK news - May 23, 2014 Category: Pharmaceuticals Source Type: news
GSK announces new commitment to improve access to vaccines with 5-year price freeze for countries graduating from GAVI Alliance support
GSK announced today that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support. (Source: GSK news)
Source: GSK news - May 20, 2014 Category: Pharmaceuticals Source Type: news
GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD
In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium ‘UMEC’ 62.5mcg (IncruseTM Ellipta®) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol ‘FSC 250/50 mcg’ (Advair ® Diskus®), was evaluated in chronic obstructive pulmonary disease (COPD) patients over 12 weeks. (Source: GSK news)
Source: GSK news - May 19, 2014 Category: Pharmaceuticals Source Type: news
GSK and Genmab announce top-line results from a pivotal head-to-head study of ofatumumab in combination with chemotherapy vs. rituximab in combination with chemotherapy for the treatment of relapsed or refractory diffuse large b-cell lymphoma
GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the Phase III study (ORCHARRD) of ofatumumab (Arzerra™) plus chemotherapy versus rituximab plus chemotherapy to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) did not meet its primary endpoint as there was no statistically significant difference in progression free survival (PFS) between the treatment arms. (Source: GSK news)
Source: GSK news - May 19, 2014 Category: Pharmaceuticals Source Type: news
GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome
GlaxoSmithKline (LSE/NYSE: GSK) today announced headline results from its second phase III study with darapladib, SOLID-TIMI 52, evaluating the efficacy of its investigational Lp-PLA2 inhibitor in adults following an acute coronary syndrome. (Source: GSK news)
Source: GSK news - May 13, 2014 Category: Pharmaceuticals Source Type: news
Anoro® (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Commission has granted marketing authorisation for Anoro®. (Source: GSK news)
Source: GSK news - May 8, 2014 Category: Pharmaceuticals Source Type: news
